<DOC>
	<DOC>NCT00436033</DOC>
	<brief_summary>Investigation of efficacy and safety of treatment with milnacipran in the treatment of fibromyalgia syndrome.</brief_summary>
	<brief_title>A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>patient with a diagnosis of fibromyalgia according to the 1990 American College of Rheumatology (ACR) criteria psychiatric illness depression of generalised anxiety disorder suicidal risk substance abuse active cardiac disease pulmonary dysfunction liver disease renal impairment autoimmune disease chronic inflammatory rheumatoid disease current systemic infection epileptic active cancer sleep apnea active peptic ulcer inflammatory bowel disease unstable endocrine disease for men : prostatic enlargement of genitourinary disorders for women : pregnancy or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>